Faron Pharmaceuticals Oy Share Discussion Threads

[arcadian] 05/4/2018 12:54

I have just asked them if a video will be available but if not I suppose the Proactive will suffice.

[paxman] 04/4/2018 11:36

Faron presenting tomorrow at Proactive in London.

Must be getting very close to top line results read out - 90 day final mortality reading was 11 March.

Tomorrow should be interesting. Anyone going ?

[arcadian] 26/3/2018 20:49

Thanks for that info. even though I cannot attend.

[aim_trader] 26/3/2018 11:10

Faron Pharmaceuticals to present to investors at the upcoming Proactive One2One Healthcare Forum on 17th May in London. For details and registration, click here:

[chrysalis99] 01/3/2018 12:56

Good to see specialist Polar Capital coming on board

[arcadian] 22/2/2018 19:19

Again today some big confident trades as has been said possibly institutions.

[chrysalis99] 22/2/2018 11:57

The webcast of the R&D day is at: hxxps://edge.media-server.com/m6/p/k75yvfgm

Impressive speakers. Lot's of detail about the science, where they're at and where they are intending to go in terms of commercialisation, routes to market, manufacturing. Covers Traumakine and Clevergen.

Mention is made of top line results very early in Q2 and also "after Easter"; I guess this may be the source of the "April" comment in post 49.

They sound confident that Traumakine PhIII results will mirror PhII.

[allonblack] 21/2/2018 21:39

There may well be results in April. Apparently he said they are scheduled to discuss pricing with NHS in May/June.

[chrysalis99] 21/2/2018 20:02

Late RNS confirming that the placing has been fully subscribed.

[arcadian] 21/2/2018 18:39

I had been hoping that mid year might be April. They certainly act and sound very confident of the outcome.

[allonblack] 21/2/2018 16:22

I spoke to someone who was there and they thought the company is clearly waiting to see how effective the drug is before discussing pricing. We will have a good idea by mid year as post read out they will immediately talk to NHS about pricing. Not long to wait.

[paxman] 21/2/2018 15:19

It's going to be put up on the website.

[chrysalis99] 21/2/2018 11:07

Is anybody attending the R&D day today at Panmure Gordon? Any feedback would be welcome.

[arcadian] 19/2/2018 18:03

I agree even though such altruism shames my more base preoccupations.

[paxman] 19/2/2018 16:55

Maybe institutions who were scaled down in this current placing ?

My view on the sales and supply infrastructure and drug batches investment is - if they are very confident in the phase 3 results matching phase 2 and don't do this investment then every day the drug is not available another 155 people die who would not otherwise have. That 210,000 US and European sufferers at 35% mortality as distinct from 8% mortality as per phase 2. The 210,000 figure comes from 70% of the 300,000 ARDS patients annually who are moderate to severe - Traumakine's target patients.

If phase 3 matches phase 2, I'm just guessing but the regulators and clinicians might be saying 'Get Traumakine out there now'.

[paxman] 19/2/2018 12:56

All in the Annual Report I think Arcadian. If I read it right and total options are around 5% then reasonable and sensible in my view.

[arcadian] 16/2/2018 16:15

Looking through the news items the BOD seem to have c 11 % and they seem to be on the fringe of options where there seems to be c 400k I`m happy with the BOD and staff holdings of shares as they are in the Market cap but it is worrying if out of the blue millions of warrants and options appear. I shall probably take this up with the company as there doesn`t seem to be a summary of these things in the results.

[paxman] 16/2/2018 16:06

Looks like 37% - pre this placing - not in public hands - board, employees. CEO has about 10%. Other directors 7%. I guess other founders and founder scientists make up much of the balance with their Chinese partner also holding.

Options about 5% of share capital from last annual report.

So management and board very motivated by existing equity stakes.

[paxman] 16/2/2018 15:51

Looks like some investors agree with you Arcadian. £ 250,000 trades going through above the placing price.

Whether you pay 805p in the placing or 840p in the market, it's all super cheap if Faron hits its regulatory and market penetration targets.

[arcadian] 16/2/2018 14:44

Certainly makes the market cap look a little conservative.

PS It doesn`t seem to have much debt but do you know the share distribution, % owned by BOD and the number of options and warrants outstanding. The latter if substantial could alter one`s perception of any share price upside.

[paxman] 15/2/2018 11:11

5 Feb RNS - Faron will have 100,000 treatments available for distribution by mid 2019 assuming regulatory approval.

Maybe they estimate 50% of market quite quickly. If so, easy to understand why. Can a clinician not treat an ARDS patient with Traumakine, if available, if it reduces mortality rates by 70-75% ?

[paxman] 15/2/2018 11:03

2 months since trial ended. 1 month until final 90 day data, as requested by FDA.

No placebo effect, and mortality end point, so should release results soon after. Maybe April.

Assuming approval in US and Europe then first year sales of $ 500m in 2019 ? Being 50,000 patients at average $ 10,000 a treatment. 50,000 patients being roughly 25% of US and Europe eligible ARDS sufferers.

Quick take up as ARDS fatal to 35% of sufferers but only 10% taking Traumakine if phase 2 replicated.

All figures illustrative and approximate and based on company presentations.

[homebrewruss] 02/10/2017 20:03

I see Faron are presenting on Thursday at proactive

Have their been any figures mentioned for what they could charge per patient if the ARDS trial is successful?

[x54v] 19/9/2017 14:37

The prior move up from February was quite something. Clearly the share price can really motor when it gets going.